CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE)-- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic ...
CARMEL, Ind., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic ...
NeurAxis announced strong Q1 2025 results, with a 39% revenue increase and expanded payer coverage, while operating loss improved. NeurAxis, Inc. reported a strong first quarter for 2025, with ...
CARMEL, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children ...
CARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...
NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and ...
Thank you for standing by and welcome to NeurAxis Fourth Quarter and Fiscal Year 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results